Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:29 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

NSS-2 BRIDGE Device in Post-Operative Pain Management

NCT03555266
View directory record Official record
Conditions
Acute Pain, Surgery, Abdominal Cancer
Interventions
NSS-2 Bridge, Sham NSS-2 BRIDGE
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Prednisolone, dipyridamole, Prednisone, Z102, placebo
Drug · Other
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Nov 2, 2026, 2:29 PM EST
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 2, 2026, 2:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II

NCT02922439
View directory record Official record
Conditions
Fatigue, Depression, Pain, Sleep Wake Disorders, Chronic Disease
Interventions
Tailored Intervention, Control Intervention
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
40 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 2, 2026, 2:29 PM EST
Active, not recruiting Not applicable Interventional Results available

Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients

NCT03686007
View directory record Official record
Conditions
Caregiver, Stage I Lung Cancer AJCC v7, Stage IA Lung Cancer AJCC v7, Stage IB Lung Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage IIA Lung Cancer AJCC v7, Stage IIB Lung Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v7
Interventions
Informational Intervention, Media Intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background ARVs, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

NCT00438464
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Interventions
Finasteride, Placebo, Prostatectomy, Laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
8
States / cities
Cleveland, Ohio • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Nov 2, 2026, 2:29 PM EST
Completed Not applicable Interventional

Postpartum Weight Loss and Exercise (PRIDE)

NCT01296516
View directory record Official record
Conditions
Gestational Diabetes, Glucose Intolerance
Interventions
Non-intervention group, Face to face, Telehelath Group
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Nov 2, 2026, 2:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay

NCT02872233
View directory record Official record
Conditions
Sunscreen Agents
Interventions
BAY 987519, SPF 15 Control
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

NCT01893515
View directory record Official record
Conditions
Dyslipidemia
Interventions
PRC-4016, Placebo
Drug
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 3 Interventional

Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)

NCT00175058
View directory record Official record
Conditions
Myocardial Infarction
Interventions
AO Therapy (aqueous oxygen)
Device
Lead sponsor
TherOx
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Nov 2, 2026, 2:29 PM EST
Recruiting Phase 1Phase 2 Interventional

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

NCT05685368
View directory record Official record
Conditions
Race-related Stress, Depression, Anxiety, Quality of Life, Stress Reaction
Interventions
ACT for SCD
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 2, 2026, 2:29 PM EST
Terminated Phase 3 Interventional Results available

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

NCT00088907
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions
docetaxel, placebo, gefitinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

NCT02873338
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dociparstat sodium, Idarubicin, Cytarabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Nov 2, 2026, 2:29 PM EST
Recruiting Phase 1Phase 2 Interventional

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

NCT06307548
View directory record Official record
Conditions
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions
Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional

Trial of VLTS-589 in Subjects With Intermittent Claudication

NCT00068133
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
Plasmid based Gene Transfer product-VLTS-589
Genetic
Lead sponsor
Valentis
Industry
Eligibility
40 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 2:29 PM EST
Completed Not applicable Interventional

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

NCT01893892
View directory record Official record
Conditions
Musculoskeletal Complications
Interventions
levocarnitine, placebo, questionnaire administration
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Nov 2, 2026, 2:29 PM EST
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Nov 2, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

NCT04200248
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
RBM-007 Injectable Solution, Aflibercept, Sham
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Nov 2, 2026, 2:29 PM EST
Recruiting Phase 2Phase 3 Interventional

BabySTrong II taVNS Feeding Trial

NCT07049952
View directory record Official record
Conditions
Feeding Delays, Neonates and Term Infants
Interventions
taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS
Device · Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
39 Weeks to 54 Weeks
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 2, 2026, 2:29 PM EST
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 2, 2026, 2:29 PM EST
Recruiting Phase 2 Interventional

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885
View directory record Official record
Conditions
Psoriasis
Interventions
D-2570 Tablet, Placebo Tablets
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 2, 2026, 2:29 PM EST